Not available
Quote | Celyad SA (NASDAQ:CYAD)
Last: | $0.47 |
---|---|
Change Percent: | -10.64% |
Open: | $0.52 |
Close: | $0.47 |
High: | $0.528 |
Low: | $0.47 |
Volume: | 49,047 |
Last Trade Date Time: | 05/18/2023 03:00:00 am |
News | Celyad SA (NASDAQ:CYAD)
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
2023-04-24 16:30:50 ET Celyad Oncology ( NASDAQ: CYAD ) received a letter on April 19th from the Nasdaq informing that the company's minimum closing bid price per share was below $1 for a period of 30 consecutive days and did not meet the minimum bid price requirement. Th...
Message Board Posts | Celyad SA (NASDAQ:CYAD)
Subject | By | Source | When |
---|---|---|---|
Good time to buy | harry crumb | investorshub | 02/25/2023 10:30:10 AM |
Better be buying, itl rip again anytime | harry crumb | investorshub | 02/16/2023 2:04:11 AM |
znewcar1: $CYAD 32% v14,3M c1.50 f22,593M H1.85 ML.62 RL1.11 LL.46 | znewcar1 | investorshangout | 02/07/2023 10:55:26 PM |
Dip for the rip!!! | Jess070283 | investorshub | 02/07/2023 3:44:03 PM |
Looks good Im in $$$$$ | INFINITI | investorshub | 02/07/2023 3:25:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...